Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
155.72
+1.74 (1.13%)
Pre-market: 156.58 +0.86 (0.55%)
Aug 28, 4:28AM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 151.36 - 157.10
52 week 127.67 - 181.81
Open 154.88
Vol / Avg. 50.00/3.94M
Mkt cap 116.76B
P/E 20.63
Div/yield 0.79/2.03
EPS 7.55
Shares 759.10M
Beta 0.55
Inst. own 82%
Oct 26, 2015
Q3 2015 Amgen Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 30, 2015
Q2 2015 Amgen Inc Earnings Call - Webcast
Jul 30, 2015
Q2 2015 Amgen Inc Earnings Release
Jun 11, 2015
Amgen Inc at Goldman Sachs Healthcare Conference
Jun 2, 2015
Amgen Inc Post-ASCO Summary Analyst Call - Webcast
Jun 1, 2015
Amgen Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin 30.78% 25.71%
Operating margin 38.66% 30.86%
EBITD margin - 43.16%
Return on average assets 9.46% 7.63%
Return on average equity 24.56% 21.55%
Employees 17,900 -
CDP Score - 64 C

Address

1 Amgen Center Dr
THOUSAND OAKS, CA 91320-1730
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Company's sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company's products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
David W. Meline Executive Vice President, Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 64
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 52
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 60
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 58
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 53
Bio & Compensation  - Reuters
Stuart A. Tross Senior Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
David A. Piacquad Senior Vice President - Business Development
Age: 58
Bio & Compensation  - Reuters
Annette Louise Such Chief Accounting Officer
Age: 46
Bio & Compensation  - Reuters